Introduction

Osteoporosis is a disease pertaining to bone health in which bone mineral density decreases which results in the fragile bone. Osteoporosis is not a life-threatening disease, however, the major issue is hip fracture due to bone fragility. (Raisz 2005, Siris et al., 2006) The 10 years’ risk of osteoporotic fracture in women above 50 years is about 5% and this risk increase to 20% by the age of 65 years. (Raisz 2005) Due to such consequences adherence of patients to antosteoporotic medications is imperative. In health care institutions, the main focus for the determination of adherence to drug therapy is through medication possession ratio (MPR). MPR is measured by dispensed quantity over a short period of time interval or overall length of the time interval. (Sperber et al., 2017) Significantly contributing risk factors in Pakistani postmenopausal women for osteoporosis are; low BMI, personal history of osteoporotic fracture, family history of osteoporotic fracture, smoking, lack of exercise, calcium deficiency, vitamin D deficiency and long term use of corticosteroid. (Khaliq et al., 2017)

The limiting factor for prevention and control of chronic disease is poor compliance with medications. (Cramer and Silverman 2006) Antiosteoerotic medications should be used chronically and may reduce the risk of fracture and indicated for the treatment and prevention of osteoporosis. (McCombs et al., 2004, Cummings 2005)
However, cost, side effects, and interference with daily life are major factors for poor compliance. (Gold and Silverman 2005, Reginster et al., 2006) Compliance objectives cannot be achieved for asymptomatic diseases like osteoporosis where patients perceive that benefit is low and the cost is high. Bisphosphonate salts are used for the treatment and prevention of osteoporosis, however, 20% patients discontinue these salts within 6 months of prescription. (Segal et al., 2003)

The main objective of the current study is to determine antiosteoporotic drug adherence among Pakistani postmenopausal women suffering from osteoporosis with the help of Medication Possession Ratio (MPR) during drug therapy. MPR is also referred to as adherence rate, it is expressed as a percent of days supply receive divided by period time. These periods may be fixed or variable depending upon the type of treatment and requirements. (Kozma et al., 2013)

**MATERIAL AND METHODS**

Prospective observational study conducted in different outpatient departments of hospitals, clinics and primary care centers of Karachi city from October 2017 to December 2018. Data has been collected by primary method from 455 postmenopausal women aged 45 and older suffering from osteoporosis, their prescriptions were evaluated and interviewed about the frequency of usage by different brands of calcium, calcium & vitamin D and vitamin D along with different brands of antiosteoporotic medications. The antiosteoporotic medications included in the study are; Risedronate, Calcitonin, Raloxifien, Gonadotropics, and Alendronate. Population is classified as lower, middle and affluent socio-economic class. Medication possession ratio is calculated in percentage from different socioeconomic areas of Karachi. Sample size of study is determined by precision analysis technique by keeping level of significance 5%. (Aparasu 2016) October 01, 2018 was considered as first purchase of medication. Study period was defined on average one year from the date of first purchase. Compliance of these medication was evaluated by Medication Possession Ratio (MPR). (Downey et al., 2006) MPR is also called adherence rate and can be determined by number of supply days per member in 365 days from the first purchase and is expressed in percentage of days within a year. Number of supply days = Number of purchases x Number of pills in packet and by frequency of dosing. For example, if women purchased Bisphosphonate once weekly tablets for one month duration, so she bought four pills. The MPR would be [4 packets x 4 pills x 7 days ÷ 365 days] x 100. Patients will be considered adherent for their medication if MPR is ≥80%. It is assumed that all tablets are taken on time as per physician’s recommendations. Statistical analysis of collected data was done on SPSS 20 version software. Descriptive statistics and inferential statistics (t-test) applied.

**RESULTS AND DISCUSSION**

Medication possession ratio is a method to calculate medication adherence and is defined as being Adherent Patients if the amount of medication furnished to the patient is at least 80% based on days supply of medication divided by the number of days patients should be consuming the medication. (Kozma et al., 2013) The risk of osteoporotic fracture reduction is not appreciable if MPR is lower than 50%, similary, if MPR is 75-80%, the future risk of osteoporotic fracture is declined 50-75%. (Siris et al., 2006) The study reveals that in lower socioeconomic class Brand C and Brand E of Risedronate salts (Harris et al., 1999) have better adherence compare to Brand A, B, and D as their MPR is ≥80%. Similarly, in the same socioeconomic class Brand C and E of Calcium and Vitamin D has MPR ≥80%. In the middle class only Brand B of Risedronate has a better adherence rate (MPR≥80%) and for Calcium and Vitamin D Brand B and C has a high adherence rate. Similarly, in affluent socioeconomic class Brand C and E has a higher adherence rate of Risedronate salts, while for calcium and Vitamin D, except Brand A, all other brands have MPR ≥80% to prove a higher adherence rate (Table I). Compare to our findings 55% adherence was reported (MPR ≥80%) with weekly Bisphosphonate salts compare to daily i.e. 40%. (Cramer et al., 2005b)
Medication possession ratio in postmenopausal osteoporotic patients: a cross sectional study

**Evaluation of four brands of another antiosteoporotic agent Calcitonin (Intranasal)(Mehta et al., 2003)** demonstrated that in lower, middle, and affluent socioeconomic classes, the higher adherence rates are reported by MPR ≥80% of Brand B, Brand C, and D and Brand B respectively. As far as concerned with Calcium and Vitamin D, Brand B and D, Brand C and D, Brand A and B have MPR ≥80% in lower, middle, and affluent socioeconomic classes respectively, so these brands have better adherence (Table II). Raloxifen, an agent used for the treatment and prevention of osteoporosis(Brixen et al., 2005) was also evaluated with two available brands. The MPR is ≥80% of Brand A in the lower class, Both Brand A and B in affluent class, while in middle socioeconomic class, none of the brands are reported to have MPR ≥80%, just Brand A reaches the figure of 79.72%. All brands of Calcium and Vitamin D are having MPR ≥80% with the treatment of Raloxifene among all socioeconomic classes (Table III).

**TABLE I - MPR of Riserdronate Brands, Calcium, Vitamin D in different Socioeconomic Classes**

| Groups (N=38) | Risedronate Brands | Lower Socioeconomic Class | Middle Socioeconomic Class | Affluent Socioeconomic Class |
|---------------|--------------------|---------------------------|-----------------------------|-----------------------------|
|               | MPR* (Calcium, Vitamin D) | MPR* (Antiresopitive) | MPR* (Calcium, Vitamin D) | MPR* (Antiresopitive) | MPR* (Calcium, Vitamin D) | MPR* (Antiresopitive) |
| 1 Brand A     | 54.79%             | 63.46%                    | 71.23%                      | 76.92%                      | 75.34%                    | 76.92%                      |
| 2 Brand B     | 78.08%             | 76.92%                    | 87.67%                      | 88.46%                      | 83.29%                    | 78.85%                      |
| 3 Brand C     | 83.29%             | 88.46%                    | 91.51%                      | 78.85%                      | 91.51%                    | 90.38%                      |
| 4 Brand D     | 71.23%             | 73.08%                    | 72.60%                      | 76.92%                      | 84.93%                    | 79.85%                      |
| 5 Brand E     | 93.15%             | 96.15%                    |                             |                             | 84.97%                    | 86.54%                      |

Average MPR* | 76.10%             | 79.61%                    | 80.75%                      | 80.28%                      | 84.00%                    | 82.50%                      |

Standard Deviation | 12.83%             | 11.51%                    | 8.95%                       | 4.41%                       | 5.17%                     | 5.09%                       |

Braz. J. Pharm. Sci. 2022;58: e19421
Hormone replacement therapy (HRT) also termed as gonadomimetics are also indicated in postmenopausal osteoporosis.(Gambacciani and Levancini 2014) Two commercial brands of these agents demonstrated that Brand B in the lower class and Brand A and B in affluent class has a higher adherence rate (MPR ≥80%), while in lower socioeconomic classes, these agents are having poor compliance. Calcium and Vitamin D demonstrated higher compliance in these groups of patients in all socioeconomic classes (MPR ≥80%) (Table IV). Another very commonly prescribed antiosteoporotic medication is Alendronate.(Bone et al., 2004) Data of overall

### TABLE II - MPR of Calcitonin Brands, Calcium, Vitamin D in different Socioeconomic Classes

| Groups (N=38) | Calcitonin Brands | Lower Socioeconomic Class | Middle Socioeconomic Class | Affluent Socioeconomic Class |
|---------------|-------------------|---------------------------|-----------------------------|-----------------------------|
|               |                   | MPR* (Calcium, Vitamin D) | MPR* (Antiresopitive)      | MPR* (Calcium, Vitamin D)   | MPR* (Antiresopitive)      |
| 1             | Brand A           | 60.27% 58.33%             | 68.49% 66.67%              | 83.56% 75.00%               |
| 2             | Brand B           | 83.29% 83.33%             | 77.81% 66.67%              | 93.15% 91.67%               |
| 3             | Brand C           | 49.32% 33.33%             | 94.52% 83.33%              | 76.71% 58.33%               |
| 4             | Brand D           | 83.56% 50.00%             | 91.67% 83.33%              | 69.86% 66.67%               |
|               | Average MPR*      | 69.11% 56.24%             | 83.12% 72.91%              | 80.82% 72.91%               |
| Standard Deviation | 14.82% 18.04%    | 10.55% 10.82%             | 8.61% 12.32%               |

### TABLE III - MPR of Raloxifen Brands, Calcium, Vitamin D in different Socioeconomic Classes

| Groups (N=38) | Raloxifen HCl Brands | Lower Socioeconomic Class | Middle Socioeconomic Class | Affluent Socioeconomic Class |
|---------------|----------------------|---------------------------|-----------------------------|-----------------------------|
|               |                      | MPR* (Calcium, Vitamin D) | MPR* (Antiresopitive)      | MPR* (Calcium, Vitamin D)   | MPR* (Antiresopitive)      |
| 1             | Brand A              | 88.35% 81.64%             | 83.28% 79.72%              | 97.26% 95.20%               |
| 2             | Brand B              | 86.30% 77.80%             | 80.82% 75.61%              | 96.43% 92.05%               |
| Average MPR*  |                      | 87.32% 79.72%             | 82.05% 77.66%              | 96.84% 93.62%               |
| Standard Deviation | 1.025% 1.92%       | 1.23% 2.055%              | 0.415% 1.575%              |

Data of overall
eight brands of Alendronate confirmed that in lower socioeconomic class Brand A and E have MPR ≥80% and these groups of patients have an acceptable adherence rate. Similarly, for middle-class Brand C, D and F are having MPR ≥80%, while in affluent class Brand B, C, D, E, F, and H have MPR ≥80%. In these groups of patients, calcium and vitamin D compliance were better (MPR ≥80%) of Brand C and E in lower socioeconomic class, Brand A, D, and E in the middle-class while Brand C, D, E and G in affluent class (Table V). Among new users of Bisphosphonate salts, the one-year adherence rate (MPR ≥80%) is about 43%.(Penning-van Beest et al., 2006)

### TABLE IV - MPR of Gonadomimetics Brands, Calcium, Vitamin D in different Socioeconomic Classes

| Groups (N=38) | Gonadomimetic Agents (HRT**) Brands | Lower Socioeconomic Class | Middle Socioeconomic Class | Affluent Socioeconomic Class |
|---------------|------------------------------------|---------------------------|---------------------------|-----------------------------|
|               | **MPR** (Calcium, Vitamin D)       | **MPR** (Antiresopitive)  | **MPR** (Calcium, Vitamin D) | **MPR** (Antiresopitive)   |
| 1 Brand A     | 84.10% 73.97%                      | 1 Brand A 92.46% 75.34%   | 1 Brand A 95.89% 93.15%    |
| 2 Brand B     | 80.82% 59.17%                      | 2 Brand B 82.46% 87.39%   | 2 Brand B 96.43% 89.04%    |
| Average MPR*  | 82.46% 66.57%                      | Average MPR* 87.46% 81.36%| Average MPR* 96.16% 91.09%|
| Standard Deviation | 1.64% 7.40%                      | Standard Deviation 5.00% 6.025% | Standard Deviation 0.270% 2.055% |

### TABLE V - MPR of Alendronate Brands, Calcium, Vitamin D in different Socioeconomic Classes

| Groups (N=38) | Alendronate Brands | Lower Socioeconomic Class | Middle Socioeconomic Class | Affluent Socioeconomic Class |
|---------------|--------------------|---------------------------|---------------------------|-----------------------------|
|               | **MPR** (Calcium, Vitamin D) | **MPR** (Antiresopitive)  | **MPR** (Calcium, Vitamin D) | **MPR** (Antiresopitive)   |
| 1 Brand A     | 78.08% 80.77%      | 1 Brand A 89.04% 78.85%   | 1 Brand A 68.49% 78.85%    |
| 2 Brand B     | 69.86% 73.08%      | 2 Brand B 79.45% 78.85%   | 2 Brand B 76.71% 84.62%    |
| 3 Brand C     | 83.29% 78.85%      | 3 Brand C 76.71% 80.77%   | 3 Brand C 87.67% 88.46%    |
| 4 Brand D     | 63.01% 65.38%      | 4 Brand D 94.52% 90.38%   | 4 Brand D 100.00% 92.31%   |
| 5 Brand E     | 83.29% 84.62%      | 5 Brand E 84.93% 76.92%   | 5 Brand E 87.67% 93.00%    |
| 6 Brand F     | 78.36% 84.62%      | 6 Brand F 87.67% 93.00%   | 6 Brand F 65.75% 82.69%    |

(continues on the next page...)
In the descriptive statistical analysis of data, it has been found that mean MPR of Risedronate in lower, middle, and affluent socioeconomic classes are 79.61%, 80.28%, and 82.50%, which is fairly logical that lower class in developing countries have low buying power of many medications. (Tanimura et al., 2014) A similar analysis of Calcitonin reveals that regardless of socioeconomic classes MPR is <80%, the probable reason is its intranasal mode of administration. (Combe et al., 1997) Mean MPR ≥80% of Raloxifen is only reported in affluent socioeconomic class despite the cost effectiveness of this medication. (Sheehy et al., 2009) HRT (Gonadomimetics) treatments are costly compare to other antiosteoporotic medications, (Zethraeus et al., 2002) because of this probable reason mean MPR of HRT is ≥80% only in middle and affluent socioeconomic classes. Despite the reasonable cost of Alendroante, mean MPR ≥80% was only found in affluent class.

Alendronate sodium and Risedronate sodium are very commonly prescribed bisphosphonate salts in the treatment and prevention of Osteoporotic fractures. (Silverman et al., 2007) These medications are oral agents, their comparative evaluation of adherence rate among different socioeconomic classes establish that Alendronate adherence rate is significantly higher among all classes compare to Risedronate, alike overall adherence rate is better significantly with Alendronate in the whole population compare to Risedronate (t = -2.537, p=0.044) (Table VI). J. Kertes et al. (2008) reported that 53% of women 45 years and above are compliant with Bisphosphonate salts and on average women discontinue these salts in seven months. (Kertes et al., 2008) In another comparison, the average persistence was 196 days compared to 216 days of Bisphosphonate salts. (Cramer et al., 2005a) In general, compliance is poor for the dosages require daily administration compare to weekly doses.

### TABLE V - MPR of Alendronate Brands, Calcium, Vitamin D in different Socioeconomic Classes

| Groups (N=38) | Alendronate Brands | Lower Socioeconomic Class | Middle Socioeconomic Class | Affluent Socioeconomic Class |
|---------------|---------------------|---------------------------|---------------------------|----------------------------|
|               | MPR* (Calcium, Vitamin D) | MPR* (Antiresopitive) | MPR* (Calcium, Vitamin D) | MPR* (Antiresopitive) |
| 7             | Brand G             | 71.23%                    | 71.15%                    | 93.15%                    |
| 8             | Brand H             | 75.34%                    | 76.92%                    | 71.23%                    |
| Average MPR*  | 76.93%              | 76.54%                    | 81.19%                    | 81.33%                    |
| Standard Deviation | 9.66%              | 6.70%                     | 7.22%                     | 11.72%                    |
|               | 7                   | Brand G                   | 71.23%                    | 76.92%                    |
| Average MPR*  | 81.19%              | 79.80%                    | 81.33%                    | 85.42%                    |
| Standard Deviation | 5.35%              | 11.72%                    | 5.46%                     | 5.46%                     |
TABLE VI - Medication Adherence with Risedronate, Alendronate, Calcium, Vitamin D in different Socioeconomic Classes

| Class                | Medication | Adherence %   | Medication | Adherence %   | t-test Significance (p<0.05) |
|----------------------|------------|---------------|------------|---------------|-----------------------------|
| **Lower Socioeconomic** | Calcium, Vitamin D | 49.67% (N=75) | Calcium, Vitamin D | 39.47% (N=15) |                             |
|                      | Alendronate sodium 70mg | 42.38% (N=64) | Risedronate sodium 35mg | 39.47% (N=15) |                             |
| **Middle Socioeconomic** | Calcium, Vitamin D | 50% (N=76) | Calcium, Vitamin D | 50% (N=12) | t = - 2.537 (p=0.044) |
|                      | Alendronate sodium 70mg | 46.71% (N=71) | Risedronate sodium 35mg | 25% (N=6) |                             |
| **Affluent Socioeconomic** | Calcium, Vitamin D | 62.20% (N=51) | Calcium, Vitamin D | 56% (N=14) |                             |
|                      | Alendronate sodium 70mg | 67.07% (N=55) | Risedronate sodium 35mg | 40% (N=10) |                             |
| **All Socioeconomic** | Calcium, Vitamin D | 52.46% (N=202) | Calcium, Vitamin D | 47.13% (N=41) |                             |
|                      | Alendronate sodium 70mg | 49.35% (N=190) | Risedronate sodium 35mg | 35.63% (N=31) |                             |

CONCLUSION

MPR is greater than 80% regardless of socioeconomic class of low-cost antosteoporotic medications. In addition to this finding, patients on once weekly oral medications are more adherent and compliant compare to oral daily or intranasal medications.

CONFLICT OF INTEREST

All authors declare no conflict of interest.

REFERENCES

Aparasu RR. Sampling methods; Chapter 107. Research methods for pharmaceutical practice and policy. 2016. United Kingdom, Pharmaceutical Press. 1:107-124.

Bone HG, Hosking D, Devogelaer J-P, Tucci JR, Emkey RD, Tonino RP, et al. Ten years’ experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med. 2004;350(12):1189-1199.

Brixen K, Abrahamsen B, Kassem M. Prevention and treatment of osteoporosis in women. Curr Obs Gynae. 2005;15(4):251-258.

Combe B, C Cohen and F Aubin. Equivalence of nasal spray and subcutaneous formulations of salmon calcitonin. Calcif Tissue Int. 1997;61(1):10-15.

Cramer J, Amonkar M, Hebborn A, Suppapanya N. Bisphosphonate dosing influences treatment adherence in postmenopausal women. Osteo Int. 2005a;16(Suppl 3):s24-s28.

Cramer JA, Amonkar MM, Hebborn A, Altman R. Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis. Current Med Res and Opin. 2005b;21(9):1453-1460.

Cramer JA, Silverman S. Persistence with bisphosphonate treatment for osteoporosis: finding the root of the problem. Am J Med. 2006;119(4):S12-S17.

Cummings SR. Bone density screening: a new level of evidence? Ann Int Med. 2005;142(3):217-219.

Downey TW, Foltz SH, Boccuzzi SJ, Omar MA, Kahler KH. Adherence and persistence associated with the
pharmacologic treatment of osteoporosis in a managed care setting. Southern Med J. 2006;99(6):570-576.

Gambacciani M, Levancini M. Management of postmenopausal osteoporosis and the prevention of fractures. Panminerva Med. 2014;56(2):115-131.

Gold D, Silverman S. Compliance with osteoporosis medications: challenges for healthcare providers. Medsc Ob/ Gyn & Women's Health. 2005;10(1):1-5.

Harris ST, Watts NB, Genant HK, McKeever CD, Hangartner T, Keller M, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. JAMA. 1999;282(14):1344-1352.

Kertes J, Dushenat M, Landes Vesterman J, Lemberger J, Bregman J, Friedman N. Factors contributing to compliance with osteoporosis medication. Isr Med Assoc J 2008;10(3):207-213.

Khalqi SA, Saad M, Fatima N, Jamil A, Khan Z, Fatima A. Evaluation of risk factors in progression of osteoporosis among postmenopausal women in karachi, pakistan. J Uni Med Dent Coll. 2017;8(2):17-23.

Kozma CM, Dickson M, Phillips AL, Meletiche DM. Medication possession ratio: implications of using fixed and variable observation periods in assessing adherence with disease-modifying drugs in patients with multiple sclerosis. Patient Prefer Adherence. 2013;7(1):509-516.

McCombs JS, Thiebaud P, McLaughlin-Miley C, Shi J. Compliance with drug therapies for the treatment and prevention of osteoporosis. Maturitas. 2004;48(3):271-287.

Mehta N, Malootian A, Gilligan J. Calcitonin for osteoporosis and bone pain. Curr Pharmaceut Design. 2003;9(32):2659-2676.

Penning-van Beest FJ, Goettsch WG, Everts JM, Herings RM. Determinants of persistence with bisphosphonates: a study in women with postmenopausal osteoporosis. Clin Ther. 2006;28(2):236-242.

Raisz LG. Screening for osteoporosis. N Engl J Med. 2005;353(2):164-171.

Reginster J-Y, Rabenda V, Neuprez A. Adherence, patient preference and dosing frequency: understanding the relationship. Bone. 2006;38(4):S2-S6.

Segal E, Tamir A, Ish-Shalom S. Compliance of osteoporotic patients with different treatment regimens. Isr Med Assoc J. 2003;5(12):859-862.

Sheehy O, Kindundu C, Barbeau M, LeLorier J. Adherence to weekly oral bisphosphonate therapy: cost of wasted drugs and fractures. Osteoporos Int. 2009;20(9):1583.